|
|
Advertisement
|
Apply by 2 October 2023
Join industry professionals, experienced physicians, and allied health professionals during the SIO 2024 Annual Scientific Meeting and participate in live IO Essentials programming.
By attending this event, you will:
- Collect tips and technical how-to's for building a successful clinical practice and career in IO.
- Expand your network, including peers and pioneers in the field.
- Get up to speed on cutting-edge IO research and treatment algorithms.
- Understand the latest clinical and translational research as it relates to patient care.
Scholarship Benefits
Accepted Scholars to the IO Essentials program at the SIO 2024 Annual Scientific Meeting will receive the following benefits:
- Complimentary membership to SIO through 31 December 2024
- Complimentary registration to the SIO 2024 Annual Scientific Meeting in Long Beach, CA 25-29 January 2024
- Stipend for travel expenses to the SIO 2024 Annual Scientific Meeting
- Local – $200 USD
- Domestic – $750 USD
- International – $1000 USD
Learn How and Apply Here
|
Advertisement
|
Key Dates and Deadlines
Call for abstracts closes: 2 October 2023
Abstract review: 9-20 October 2023
Abstract notifications: Week of 30 October 2023
|
Advertisement
|
IO Awareness Week Presents:
During this free webinar, faculty will review cases and discuss treatment options, device selection and usage, tips and tricks, and lessons learned from their own experiences. Attendees are encouraged to bring their own cases for discussion!
This webinar is jointly supported by BD, Boston Scientific, Stryker, and Varian Medical Systems.
Learn More and Register Here
|
Advertisement
|
SIO Submits Revisions to NCCN Soft Tissue Sarcoma Cancer Guidelines
The Society of Interventional Oncology submitted updates to the NCCN Soft Tissue Sarcoma Guidelines. Authored by Jack Jennings, MD, PhD, Joseph Erinjeri, MD, PhD, and Daehee Kim, MD, this letter requests two specific changes to the NCCN Soft Tissue Sarcoma Cancer Guidelines: 1) the addition of drug-eluting bead chemoembolization as a treatment option for desmoid tumors and transarterial chemoembolization (TACE) as a treatment option for selective extra-abdominal desmoid tumors; and 2) clarifying embolization procedures to include transarterial bland embolization, chemoembolization, and radioembolization for non-lung metastases treatment.
Download the complete 2023 letter here.
|
Advertisement
|
Promoted by Medtronic
Outcomes in the first 100 patients treated with the OsteoCool™ Radiofrequency Ablation System from the OPuS One trial were recently published in the November edition of the Journal of Vascular and Interventional Radiology (JVIR). Learn more about the largest prospective study in radiofrequency ablation for bone metastases. Read More
|
Efficacy and Safety of Distal Radial Access for Transcatheter Arterial Chemoembolization (TACE) of the Liver
Journal of Personalized Medicine
The distal radial artery has emerged as an alternative vascular-access site to conventional transfemoral and transradial approaches. The main advantage over the conventional transradial route is the reduced risk of radial artery occlusion, especially in those patients who, for various clinical reasons, have to undergo repeated endovascular procedures. This study aims to assess the efficacy and safety of distal radial access for transcatheter arterial chemoembolization of the liver. Read More
|
|
IO Insights
The Society of Interventional Oncology
2001 K Street NW, 3rd Floor North | Washington, DC 20006 USA
202-367-1164 | Contact Us
www.sio-central.org
|
|
|
|
|
|